Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Rating of “Hold” from Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has earned a consensus recommendation of “Hold” from the ten brokerages that are currently covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $10.78.

A number of equities research analysts have weighed in on ZNTL shares. Oppenheimer reissued an “outperform” rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Wedbush raised shares of Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price objective on the stock in a research note on Monday, August 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Monday, August 12th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ZNTL. Wealth Enhancement Advisory Services LLC bought a new stake in Zentalis Pharmaceuticals in the first quarter worth approximately $680,000. Commonwealth Equity Services LLC lifted its position in shares of Zentalis Pharmaceuticals by 12.2% during the 1st quarter. Commonwealth Equity Services LLC now owns 60,895 shares of the company’s stock valued at $960,000 after acquiring an additional 6,640 shares during the period. Carson Advisory Inc. bought a new position in Zentalis Pharmaceuticals during the first quarter worth $201,000. 49 Wealth Management LLC bought a new position in Zentalis Pharmaceuticals during the first quarter worth $172,000. Finally, ProShare Advisors LLC grew its holdings in Zentalis Pharmaceuticals by 9.0% in the first quarter. ProShare Advisors LLC now owns 15,436 shares of the company’s stock worth $243,000 after purchasing an additional 1,274 shares during the period.

Zentalis Pharmaceuticals Stock Up 21.6 %

Shares of ZNTL stock opened at $3.32 on Monday. Zentalis Pharmaceuticals has a twelve month low of $2.66 and a twelve month high of $18.24. The stock’s fifty day simple moving average is $3.30 and its 200 day simple moving average is $6.00. The firm has a market capitalization of $236.08 million, a P/E ratio of -1.22 and a beta of 1.74.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Friday, August 9th. The company reported ($1.24) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.40). During the same period in the prior year, the company posted ($1.85) earnings per share. As a group, equities research analysts expect that Zentalis Pharmaceuticals will post -3.02 EPS for the current fiscal year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.